Trial reportCanadian respiratory journal2026
Adjunctive Short-Wave Diathermy to High-Frequency Chest Wall Oscillation for Acute Exacerbation of COPD: A Randomized Controlled Trial.
Trial report in Canadian respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adjunctive Short-Wave Diathermy to High-Frequency Chest Wall Oscillation for Acute Exacerbation of COPD: A Randomized Controlled Trial.Canadian respiratory journal · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of combining short-wave diathermy (SWD) with high-frequency chest wall oscillation (HFCWO) compared with HFCWO alone and routine treatment in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
methodsThis single-center, parallel-group randomized controlled trial enrolled 89 patients with AECOPD admitted to Yongkang First People's Hospital between March 2024 and March 2025. Participants were randomly assigned (1:1:1) to receive routine treatment alone (control group), routine treatment plus HFCWO (HFCWO group), or routine treatment plus combined SWD and HFCWO (combined group) for 72 h. Primary and secondary outcomes were assessed at baseline and after 72 h of intervention, with both within-group and between-group comparisons performed. Primary outcomes included changes in the COPD Assessment Test (CAT) and Breathlessness, Cough, and Sputum Scale (BCSS) scores. Secondary outcomes included lung function parameters (FEV
resultsAfter the 72-h intervention, the combined therapy group demonstrated significantly greater reductions in CAT and BCSS scores compared with both the HFCWO group and the control group (p < 0.05). Combined therapy also achieved superior improvements in arterial blood gas parameters (PaO
conclusionsThe combined intervention significantly improves respiratory symptoms, arterial oxygenation, and sputum clearance in patients with AECOPD compared with HFCWO alone or routine treatment. The addition of thermal therapy enhances the clinical efficacy of mechanical airway clearance, offering a feasible adjunctive strategy for acute-phase management of AECOPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.